Development and Validation of a Scoring System to Predict Outcomes of Patients with Primary Biliary Cirrhosis Receiving Ursodeoxycholic Acid Therapy

Willem J. Lammers, Gideon M. Hirschfield, Christophe Corpechot, Frederik Nevens, Keith D. Lindor, Harry L A Janssen, Annarosa Floreani, Cyriel Y. Ponsioen, Marlyn J. Mayo, Pietro Invernizzi, Pier M. Battezzati, Albert Parés, Andrew K. Burroughs, Andrew L. Mason, Kris V. Kowdley, Teru Kumagi, Maren H. Harms, Palak J. Trivedi, Raoul Poupon, Angela Cheung & 4 others Ana Lleo, Llorenç Caballeria, Bettina E. Hansen, Henk R. Van Buuren

Research output: Contribution to journalArticle

126 Citations (Scopus)

Abstract

Background & Aims Approaches to risk stratification for patients with primary biliary cirrhosis (PBC) are limited, single-center based, and often dichotomous. We aimed to develop and validate a better model for determining prognoses of patients with PBC. Methods We performed an international, multicenter meta-analysis of 4119 patients with PBC treated with ursodeoxycholic acid at liver centers in 8 European and North American countries. Patients were randomly assigned to derivation (n = 2488 [60%]) and validation cohorts (n = 1631 [40%]). A risk score (GLOBE score) to predict transplantation-free survival was developed and validated with univariate and multivariable Cox regression analyses using clinical and biochemical variables obtained after 1 year of ursodeoxycholic acid therapy. Risk score outcomes were compared with the survival of age-, sex-, and calendar time-matched members of the general population. The prognostic ability of the GLOBE score was evaluated alongside those of the Barcelona, Paris-1, Rotterdam, Toronto, and Paris-2 criteria. Results Age (hazard ratio = 1.05; 95% confidence interval [CI]: 1.04-1.06; P 0.30 had significantly shorter times of transplant-free survival than matched healthy individuals (P

Original languageEnglish (US)
Pages (from-to)1804-1812e4
JournalGastroenterology
Volume149
Issue number7
DOIs
StatePublished - Dec 1 2015

Fingerprint

Ursodeoxycholic Acid
Biliary Liver Cirrhosis
Paris
Survival
Therapeutics
Meta-Analysis
Transplantation
Regression Analysis
Confidence Intervals
Transplants
Liver
Population

Keywords

  • Autoimmune Liver Disease
  • Cholestasis
  • Predictive Factor
  • Prognosis

ASJC Scopus subject areas

  • Gastroenterology

Cite this

Lammers, W. J., Hirschfield, G. M., Corpechot, C., Nevens, F., Lindor, K. D., Janssen, H. L. A., ... Van Buuren, H. R. (2015). Development and Validation of a Scoring System to Predict Outcomes of Patients with Primary Biliary Cirrhosis Receiving Ursodeoxycholic Acid Therapy. Gastroenterology, 149(7), 1804-1812e4. https://doi.org/10.1053/j.gastro.2015.07.061

Development and Validation of a Scoring System to Predict Outcomes of Patients with Primary Biliary Cirrhosis Receiving Ursodeoxycholic Acid Therapy. / Lammers, Willem J.; Hirschfield, Gideon M.; Corpechot, Christophe; Nevens, Frederik; Lindor, Keith D.; Janssen, Harry L A; Floreani, Annarosa; Ponsioen, Cyriel Y.; Mayo, Marlyn J.; Invernizzi, Pietro; Battezzati, Pier M.; Parés, Albert; Burroughs, Andrew K.; Mason, Andrew L.; Kowdley, Kris V.; Kumagi, Teru; Harms, Maren H.; Trivedi, Palak J.; Poupon, Raoul; Cheung, Angela; Lleo, Ana; Caballeria, Llorenç; Hansen, Bettina E.; Van Buuren, Henk R.

In: Gastroenterology, Vol. 149, No. 7, 01.12.2015, p. 1804-1812e4.

Research output: Contribution to journalArticle

Lammers, WJ, Hirschfield, GM, Corpechot, C, Nevens, F, Lindor, KD, Janssen, HLA, Floreani, A, Ponsioen, CY, Mayo, MJ, Invernizzi, P, Battezzati, PM, Parés, A, Burroughs, AK, Mason, AL, Kowdley, KV, Kumagi, T, Harms, MH, Trivedi, PJ, Poupon, R, Cheung, A, Lleo, A, Caballeria, L, Hansen, BE & Van Buuren, HR 2015, 'Development and Validation of a Scoring System to Predict Outcomes of Patients with Primary Biliary Cirrhosis Receiving Ursodeoxycholic Acid Therapy', Gastroenterology, vol. 149, no. 7, pp. 1804-1812e4. https://doi.org/10.1053/j.gastro.2015.07.061
Lammers, Willem J. ; Hirschfield, Gideon M. ; Corpechot, Christophe ; Nevens, Frederik ; Lindor, Keith D. ; Janssen, Harry L A ; Floreani, Annarosa ; Ponsioen, Cyriel Y. ; Mayo, Marlyn J. ; Invernizzi, Pietro ; Battezzati, Pier M. ; Parés, Albert ; Burroughs, Andrew K. ; Mason, Andrew L. ; Kowdley, Kris V. ; Kumagi, Teru ; Harms, Maren H. ; Trivedi, Palak J. ; Poupon, Raoul ; Cheung, Angela ; Lleo, Ana ; Caballeria, Llorenç ; Hansen, Bettina E. ; Van Buuren, Henk R. / Development and Validation of a Scoring System to Predict Outcomes of Patients with Primary Biliary Cirrhosis Receiving Ursodeoxycholic Acid Therapy. In: Gastroenterology. 2015 ; Vol. 149, No. 7. pp. 1804-1812e4.
@article{de52463b701442aa8a450fd214617509,
title = "Development and Validation of a Scoring System to Predict Outcomes of Patients with Primary Biliary Cirrhosis Receiving Ursodeoxycholic Acid Therapy",
abstract = "Background & Aims Approaches to risk stratification for patients with primary biliary cirrhosis (PBC) are limited, single-center based, and often dichotomous. We aimed to develop and validate a better model for determining prognoses of patients with PBC. Methods We performed an international, multicenter meta-analysis of 4119 patients with PBC treated with ursodeoxycholic acid at liver centers in 8 European and North American countries. Patients were randomly assigned to derivation (n = 2488 [60{\%}]) and validation cohorts (n = 1631 [40{\%}]). A risk score (GLOBE score) to predict transplantation-free survival was developed and validated with univariate and multivariable Cox regression analyses using clinical and biochemical variables obtained after 1 year of ursodeoxycholic acid therapy. Risk score outcomes were compared with the survival of age-, sex-, and calendar time-matched members of the general population. The prognostic ability of the GLOBE score was evaluated alongside those of the Barcelona, Paris-1, Rotterdam, Toronto, and Paris-2 criteria. Results Age (hazard ratio = 1.05; 95{\%} confidence interval [CI]: 1.04-1.06; P 0.30 had significantly shorter times of transplant-free survival than matched healthy individuals (P",
keywords = "Autoimmune Liver Disease, Cholestasis, Predictive Factor, Prognosis",
author = "Lammers, {Willem J.} and Hirschfield, {Gideon M.} and Christophe Corpechot and Frederik Nevens and Lindor, {Keith D.} and Janssen, {Harry L A} and Annarosa Floreani and Ponsioen, {Cyriel Y.} and Mayo, {Marlyn J.} and Pietro Invernizzi and Battezzati, {Pier M.} and Albert Par{\'e}s and Burroughs, {Andrew K.} and Mason, {Andrew L.} and Kowdley, {Kris V.} and Teru Kumagi and Harms, {Maren H.} and Trivedi, {Palak J.} and Raoul Poupon and Angela Cheung and Ana Lleo and Lloren{\cc} Caballeria and Hansen, {Bettina E.} and {Van Buuren}, {Henk R.}",
year = "2015",
month = "12",
day = "1",
doi = "10.1053/j.gastro.2015.07.061",
language = "English (US)",
volume = "149",
pages = "1804--1812e4",
journal = "Gastroenterology",
issn = "0016-5085",
publisher = "W.B. Saunders Ltd",
number = "7",

}

TY - JOUR

T1 - Development and Validation of a Scoring System to Predict Outcomes of Patients with Primary Biliary Cirrhosis Receiving Ursodeoxycholic Acid Therapy

AU - Lammers, Willem J.

AU - Hirschfield, Gideon M.

AU - Corpechot, Christophe

AU - Nevens, Frederik

AU - Lindor, Keith D.

AU - Janssen, Harry L A

AU - Floreani, Annarosa

AU - Ponsioen, Cyriel Y.

AU - Mayo, Marlyn J.

AU - Invernizzi, Pietro

AU - Battezzati, Pier M.

AU - Parés, Albert

AU - Burroughs, Andrew K.

AU - Mason, Andrew L.

AU - Kowdley, Kris V.

AU - Kumagi, Teru

AU - Harms, Maren H.

AU - Trivedi, Palak J.

AU - Poupon, Raoul

AU - Cheung, Angela

AU - Lleo, Ana

AU - Caballeria, Llorenç

AU - Hansen, Bettina E.

AU - Van Buuren, Henk R.

PY - 2015/12/1

Y1 - 2015/12/1

N2 - Background & Aims Approaches to risk stratification for patients with primary biliary cirrhosis (PBC) are limited, single-center based, and often dichotomous. We aimed to develop and validate a better model for determining prognoses of patients with PBC. Methods We performed an international, multicenter meta-analysis of 4119 patients with PBC treated with ursodeoxycholic acid at liver centers in 8 European and North American countries. Patients were randomly assigned to derivation (n = 2488 [60%]) and validation cohorts (n = 1631 [40%]). A risk score (GLOBE score) to predict transplantation-free survival was developed and validated with univariate and multivariable Cox regression analyses using clinical and biochemical variables obtained after 1 year of ursodeoxycholic acid therapy. Risk score outcomes were compared with the survival of age-, sex-, and calendar time-matched members of the general population. The prognostic ability of the GLOBE score was evaluated alongside those of the Barcelona, Paris-1, Rotterdam, Toronto, and Paris-2 criteria. Results Age (hazard ratio = 1.05; 95% confidence interval [CI]: 1.04-1.06; P 0.30 had significantly shorter times of transplant-free survival than matched healthy individuals (P

AB - Background & Aims Approaches to risk stratification for patients with primary biliary cirrhosis (PBC) are limited, single-center based, and often dichotomous. We aimed to develop and validate a better model for determining prognoses of patients with PBC. Methods We performed an international, multicenter meta-analysis of 4119 patients with PBC treated with ursodeoxycholic acid at liver centers in 8 European and North American countries. Patients were randomly assigned to derivation (n = 2488 [60%]) and validation cohorts (n = 1631 [40%]). A risk score (GLOBE score) to predict transplantation-free survival was developed and validated with univariate and multivariable Cox regression analyses using clinical and biochemical variables obtained after 1 year of ursodeoxycholic acid therapy. Risk score outcomes were compared with the survival of age-, sex-, and calendar time-matched members of the general population. The prognostic ability of the GLOBE score was evaluated alongside those of the Barcelona, Paris-1, Rotterdam, Toronto, and Paris-2 criteria. Results Age (hazard ratio = 1.05; 95% confidence interval [CI]: 1.04-1.06; P 0.30 had significantly shorter times of transplant-free survival than matched healthy individuals (P

KW - Autoimmune Liver Disease

KW - Cholestasis

KW - Predictive Factor

KW - Prognosis

UR - http://www.scopus.com/inward/record.url?scp=84952986849&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84952986849&partnerID=8YFLogxK

U2 - 10.1053/j.gastro.2015.07.061

DO - 10.1053/j.gastro.2015.07.061

M3 - Article

VL - 149

SP - 1804-1812e4

JO - Gastroenterology

JF - Gastroenterology

SN - 0016-5085

IS - 7

ER -